{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:59:16Z","timestamp":1764277156832,"version":"3.45.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.resmer.2022.100931","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:39:01Z","timestamp":1655761141000},"page":"100931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy of empiric macrolides versus fluoroquinolones in community-acquired pneumonia associated with atypical bacteria: A meta-analysis"],"prefix":"10.1016","volume":"82","author":[{"given":"Ahmed","family":"Basilim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haytham","family":"Wali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Rabaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-8637","authenticated-orcid":false,"given":"Khalid","family":"Eljaaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.resmer.2022.100931_bib0001","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/ijms17122120","article-title":"Microbial Etiology of Pneumonia: epidemiology, Diagnosis and Resistance Patterns","volume":"17","author":"Cilloniz","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resmer.2022.100931_bib0002","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archinte.1997.00440360129015","article-title":"Incidence of community acquired pneumonia requiring hospitalization: results of a population based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group","volume":"157","author":"Marston","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.resmer.2022.100931_bib0003","unstructured":"WHO Fact sheet N\u00b0331; Updated November 2015. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs331\/en\/."},{"key":"10.1016\/j.resmer.2022.100931_bib0004","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1378\/chest.125.6.2140","article-title":"Treatment costs of community-acquired pneumonia in an employed population","volume":"125","author":"Colice","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100931_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1370\/afm.1993","article-title":"Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis","volume":"14","author":"Marchello","year":"2016","journal-title":"Ann Fam Med"},{"issue":"7","key":"10.1016\/j.resmer.2022.100931_bib0006","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and the Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.resmer.2022.100931_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.resmer.2022.100931_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2019.1680116","article-title":"Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia","volume":"32","author":"Eljaaly","year":"2020","journal-title":"J Chemother"},{"issue":"6","key":"10.1016\/j.resmer.2022.100931_bib0009","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jiac.2020.01.005","article-title":"Photosensitivity induced by lomefloxacin versus other fluoroquinolones: a meta-analysis","volume":"26","author":"Eljaaly","year":"2020","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.resmer.2022.100931_bib0010","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.resmer.2022.100931_bib0011","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-Lactam plus macrolides or beta lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.resmer.2022.100931_bib0012","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults","volume":"9","author":"Eliakim-Raz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7489","key":"10.1016\/j.resmer.2022.100931_bib0013","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis","volume":"330","author":"Mills","year":"2005","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.resmer.2022.100931_bib0014","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/archinte.165.17.1992","article-title":"Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials","volume":"165","author":"Shefet","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.resmer.2022.100931_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12879-017-2495-5","article-title":"Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis","volume":"17","author":"Eljaaly","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"19","key":"10.1016\/j.resmer.2022.100931_bib0016","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3390\/jcm10194321","article-title":"Efficacy of empiric antibiotic coverage in community-acquired pneumonia associated with each atypical bacteria: a meta-analysis","volume":"10","author":"Eljaaly","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.resmer.2022.100931_bib0017","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/INF.0b013e3180cbd2c7","article-title":"Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia","volume":"26","author":"Bradley","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl1","key":"10.1016\/j.resmer.2022.100931_bib0018","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.resmer.2022.100931_bib0019","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.resmer.2022.100931_bib0020","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.resmer.2022.100931_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1469-0691.2004.0906.x","article-title":"International Gatifloxacin Study Group. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia","volume":"10","author":"Lode","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 3","key":"10.1016\/j.resmer.2022.100931_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.0070s3011.x","article-title":"Structure\u2013activity relationships of ketolides vs. macrolides","volume":"7","author":"Douthwaite","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.resmer.2022.100931_bib0023","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cmi.2018.08.002","article-title":"Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States","volume":"25","author":"Eljaaly","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.resmer.2022.100931_bib0024","first-page":"535","article-title":"Multivalent cations interactions with fluoroquinolones or tetracyclines: a cross-sectional study","volume":"26","author":"Eljaaly","year":"2020","journal-title":"Saudi J Biol Sci"},{"issue":"4","key":"10.1016\/j.resmer.2022.100931_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.resmer.2022.100931_bib0026","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.resmer.2022.100931_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.diagmicrobio.2012.08.024","article-title":"Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998\u20132011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.resmer.2022.100931_bib0028","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/313677","article-title":"New uses for new and old quinolones and the challenge of resistance","volume":"30","author":"Hooper","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.resmer.2022.100931_bib0029","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1128\/AAC.00237-11","article-title":"Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.resmer.2022.100931_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/37.suppl_A.1","article-title":"In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens","volume":"37","author":"Baquero","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.resmer.2022.100931_bib0031","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s101560070013","article-title":"Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae","volume":"6","author":"Ikejima","year":"2000","journal-title":"J Infect Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.resmer.2022.100931_bib0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/45.suppl_3.41","article-title":"Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp","volume":"45","author":"Dubois","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resmer.2022.100931_bib0033","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00134-002-1304-8","article-title":"Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy","volume":"28","author":"Gacouin","year":"2002","journal-title":"Intens Care Med"},{"key":"10.1016\/j.resmer.2022.100931_bib0034","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides","volume":"40","author":"Bl\u00e1zquez Garrido","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resmer.2022.100931_bib0035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaires disease","volume":"128","author":"Sabri\u00e0","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100931_bib0036","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resmer.2022.100931_bib0037","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cmi.2017.02.030","article-title":"Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis","volume":"23","author":"Garcia-Vidal","year":"2017","journal-title":"Clin Microbiol Infect"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:55:48Z","timestamp":1762908948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041222000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"alternative-id":["S2590041222000472"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100931","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of empiric macrolides versus fluoroquinolones in community-acquired pneumonia associated with atypical bacteria: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100931"}}